DUBLIN--(BUSINESS WIRE)--The "Global IL-17 Biologics Market (2023 Edition): Analysis By Indication, By Drug (Secukinumab, Ixekizumab, Bimekizumab, Brodalumab), By Region, By Country: Market Insights ...

Women with psoriasis show shorter drug survival for biologics, including IL-17/23 inhibitors, due to lower satisfaction and more frequent adverse events. The study used the Dutch BioCAPTURE registry ...

Researchers have shown that a novel antibody generated to target an 'essential amino acid sequence’ of both interleukin-17A and F has greater activity and potentially fewer side effects than existing ...

A review of 10 articles finds that nearly 9% of adverse event (AE) reports with biologics used to treat psoriasis were gastrointestinal (GI)-related and suggests that the relative rate may be higher ...

Authors of an observational cohort study published in the Journal of the European Academy of Dermatology and Venereology investigated the efficacy of interleukin-17 inhibitors (IL-17i) for the ...